DRKS00012864已完成不适用
Effect of CTLA-4-Ig on human B lymphocyte function and specificity for citrullinated protein antigens in rheumatoid arthritis (RA) - Abatacept and B cells
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •rheumatoide arthritis
- •informed consent
- •treatment with abatacept
- •treatment start after 01.01.2015
排除标准
- •prior therapy with ritxuimab, JAk-Inhibitors, cyclophosphamide
- •malignant disease
研究者
相似试验
已完成
4 期
Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)Rheumatic DiseasesRheumatoid ArthritisNCT03492658Leiden University Medical Center46
已完成
2 期
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT00505375National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)112
已完成
2 期
Effect of CTLA4-Ig on severe asthma (ECSA) study ; Double blind, placebo controlled, phase IIa trial of CTLA4-Ig (abatacept) on severe asthmaSevere asthmaJPRN-UMIN000016283ational Hospital Organization, Sagamihara National Hospital30
已完成
不适用
Humoral and T-cell responses to a fourth dose of BNT162b2 and mRNA-1273 COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study.Hematological diseasesJPRN-UMIN000048638Kobe City Medical Center General Hospital20
终止
2 期
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial SarcomaSynovial SarcomaNCT00140855Ludwig Institute for Cancer Research6